Nykode Therapeutics ASA - Asset Resilience Ratio

Latest as of December 2025: 60.32%

Nykode Therapeutics ASA (NYKD) has an Asset Resilience Ratio of 60.32% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Nykode Therapeutics ASA's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Nkr60.29 Million

≈ $6.34 Million USD Cash + Short-term Investments

Total Assets

Nkr99.95 Million

≈ $10.52 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Nykode Therapeutics ASA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Nykode Therapeutics ASA.

Liquid Assets Composition Over Time

This chart breaks down Nykode Therapeutics ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Nykode Therapeutics ASA balance sheet liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr60.29 Million	60.32%
Short-term Investments	Nkr0.00	0%
Total Liquid Assets	Nkr60.29 Million	60.32%

Asset Resilience Insights

Very High Liquidity: Nykode Therapeutics ASA maintains exceptional liquid asset reserves at 60.32% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Nykode Therapeutics ASA Industry Peers by Asset Resilience Ratio

Compare Nykode Therapeutics ASA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Nykode Therapeutics ASA (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Nykode Therapeutics ASA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	60.32%	Nkr60.29 Million ≈ $6.34 Million	Nkr99.95 Million ≈ $10.52 Million	-14.49pp
2024-12-31	74.81%	Nkr114.82 Million ≈ $12.08 Million	Nkr153.48 Million ≈ $16.15 Million	-2.98pp
2023-12-31	77.79%	Nkr161.95 Million ≈ $17.04 Million	Nkr208.19 Million ≈ $21.91 Million	-15.15pp
2022-12-31	92.94%	Nkr205.84 Million ≈ $21.66 Million	Nkr221.48 Million ≈ $23.31 Million	+88.36pp
2021-12-31	4.58%	Nkr12.17 Million ≈ $1.28 Million	Nkr265.56 Million ≈ $27.94 Million	-6.26pp
2020-12-31	10.84%	Nkr24.94 Million ≈ $2.62 Million	Nkr230.03 Million ≈ $24.21 Million	-54.10pp
2019-12-31	64.94%	Nkr190.33 Million ≈ $20.03 Million	Nkr293.08 Million ≈ $30.84 Million	-28.71pp
2018-12-31	93.65%	Nkr143.60 Million ≈ $15.11 Million	Nkr153.34 Million ≈ $16.14 Million	-2.58pp
2017-12-31	96.23%	Nkr206.37 Million ≈ $21.72 Million	Nkr214.47 Million ≈ $22.57 Million	+86.31pp
2016-12-31	9.92%	Nkr2.47 Million ≈ $260.24K	Nkr24.93 Million ≈ $2.62 Million	--

pp = percentage points

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$166.04 Million

Nkr1.58 Billion NOK

Market Cap Rank

#17364 Global

#147 in Norway

Share Price

Nkr4.03

Change (1 day)

+1.51%

52-Week Range

Nkr1.58 - Nkr4.99

All Time High

Nkr91.25